A randomized, double-blind, placebo-controlled, multi-center study was performed by former Cetero Research at two United States (U.S.) clinical research sites – one in Fargo, North Dakota and the other in St. Charles, Missouri. To be included, subjects had to be between 21 and 79 years of age, have a low habitual fatty fish and seafood intake (defined as the selleck inhibitor intake of fatty fish and seafood at a frequency

not to exceed twice per month), and have borderline high or high fasting serum TG levels (defined as a fasting TG level of 150–499 mg/dL at Screening visit, inclusive). Subjects were not eligible for study participation if they tested positive for drug or alcohol screens, tested positive for pregnancy (for women of child-bearing potential), were on lipid lowering medications or omega-3 supplementation, had a body mass index (BMI)

≥35 kg/m2, had CVD or other co-morbidities, bleeding disorders, hypertension, familial hypercholesterolemia, coronary, peripheral or cerebral vascular disease, or allergy to fish or crustaceans. The primary objective of the study was to assess the effects on fasting serum TG levels during 12 weeks of daily supplementation with four different daily doses of SuperbaTM krill oil (0.5, 1.0, 2.0 and 4.0 g). Qualifying subjects were randomly and evenly allocated into 5 study groups. Randomization was stratified by gender. Subjects were instructed to avoid fish and seafood meals Selleckchem NVP-BEZ235 PAK6 36 hours before each clinic visit and to avoid consuming alcohol in the 24 hours before each scheduled visit. A total of 5 visits were included: one for screening, one for randomization and collection of baseline information, one at day 7 to ensure the test products were being taken appropriately, and two efficacy visits (6 and 12 weeks) when blood was drawn. Krill oil capsules were provided by Aker BioMarine ASA (Oslo, Norway) and olive oil (placebo) was obtained from Ruiz-Canela e Hijos (Sevilla, Spain). The fatty acid and

lipid profiles of the study products are presented in Table 1. All subjects were required to consume 8×500 mg capsules daily for the 12-week intervention period; 4 capsules in the morning with water before breakfast, and 4 capsules in the evening with water before dinner. Subjects allocated to the placebo group consumed 8 placebo capsules daily whereas subjects allocated to krill oil took 1, 2, 4 or 8 krill oil capsules and the remainder as placebo. The group that was assigned 1 krill oil capsule per day took it with the morning meal, otherwise the krill oil and placebo capsules were distributed evenly amongst the morning and evening doses. The varying doses of krill oil (i.e., 0, 0.5, 1, 2, and 4 g/day) corresponded to daily intakes of EPA + DHA of 0, 100, 200, 400, and 800 mg/day, respectively.